news:: Drug Discovery in Academia
Back to Drug Discovery in Academia

AstraZeneca Pharmaceuticals

John Reid, PhD, MBA
John Reid is a business development leader in research alliances and licensing with a supporting scientific career in drug discovery and molecular biology. He has a record of success in delivering new drugs for clinical development by leveraging critical science and business assets in strategic alliances.  He is currently responsible for early stage licensing and business development in Neuroscience at AstraZeneca Pharmaceuticals.  Previous roles at AstraZeneca include, Head of the Molecular Sciences Department, responsible for exploratory research in CNS, Global Alliance Management Director, and Strategic Planning/Knowledge Management Director. Before joining Astra in 1997, he was a scientist and group leader at the Glaxo Institute for Molecular Biology in Geneva, Switzerland, and a scientist at Genentech in San Francisco. He is a graduate of the University of California, Berkeley, (Ph D), UC Davis (B Sc), U. Penn-Wharton School (CPD), and LeBow College-Drexel (MBA).  He has authored 25 publications in professional journals, presented over 30 invited seminars, and was recognized in 2008 and 2010 for the “Deal of Distinction Award” from the Licensing Executive Society. 

AstraZeneca Pharmaceuticals
AstraZeneca is a global, innovation-driven, integrated biopharmaceutical company.
Our mission is to make a meaningful difference to patient health through great medicines that bring benefit for patients and add value for our stakeholders and society.
We discover, develop, manufacture and market prescription medicines for six important areas of healthcare, which include some of the world’s most serious illnesses: cancer, cardiovascular, gastrointestinal, infection, neuroscience, and respiratory and inflammation.

Share This Information